ponatinib
Sign in to saveAlso known as AP24534, Iclusig®, AP 24534, Ponatinibum
Ponatinib, sold under the brand name Iclusig, is a medication used for the treatment of chronic myeloid leukemia and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia. It was developed by Ariad Pharmaceuticals. It is a multi-targeted tyrosine-kinase inhibitor. Some forms of chronic myeloid leukemia, those that have the T315I mutation, are resistant to current therapies such as imatinib. Ponatinib has been designed to be effective against these types of tumors.
Key facts
- Drug.UNII
- 4340891KFS
- Drug.KEGG
- D09950
- Drug.ChEBI
- 78543
- Drug.ChEMBL
- 1171837
- Drug.image
- Ponatinib2DACS.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 275
- Drug.image2
- Ponatinib molecule ball.png
- Drug.image_class2
- bg-transparent
- Drug.tradename
- Iclusig
- Drug.MedlinePlus
- a613029
- Drug.DailyMedID
- Ponatinib
- Drug.pregnancy_AU
- D
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- L01
- Drug.ATC_suffix
- EA05
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
via Wikipedia infobox
Research
1,466 papers- Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.JAMA · 2024
- Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.The Lancet. Haematology · 2023
- Ponatinib Drives Cardiotoxicity by S100A8/A9-NLRP3-IL-1β Mediated Inflammation.Circulation research · 2023
- Ponatinib: A comprehensive drug profile.Profiles of drug substances, excipients, and related methodology · 2024
- Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024
via PubMed
Wikidata facts
- Subclass of
- unsaturated compound
- Mass
- 532.22
- Has use
- medication
Show 8 more facts
- Commons category
- Ponatinib
- chemical formula
- C₂₉H₂₇F₃N₆O
- medical condition treated
- gastrointestinal stromal tumor
- canonical SMILES
- CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5
- World Health Organisation international non-proprietary name
- ponatinib
- subject has role
- tyrosine-kinase inhibitor
- physically interacts with
- ABL proto-oncogene 1, non-receptor tyrosine kinase
- stylized name
- PONATinib
Sources (6)
via Wikidata · CC0
~6 min read
Encyclopedic overview
8 sectionsContents
- Medical uses
- Adverse effects
- Clinical trials
- Mechanism of action
- Society and culture
- Legal status
- Economics
- References
Ponatinib, sold under the brand name Iclusig, is a medication used for the treatment of chronic myeloid leukemia and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia. It was developed by Ariad Pharmaceuticals. It is a multi-targeted tyrosine-kinase inhibitor. Some forms of chronic myeloid leukemia, those that have the T315I mutation, are resistant to current therapies such as imatinib. Ponatinib has been designed to be effective against these types of tumors.
Ponatinib was approved for medical use in the United States in December 2012, and in the European Union in July 2013.
Excerpted from Wikipedia’s “ponatinib” article, available under the CC BY-SA 4.0 licence.